Document is current
Any future updates will be listed below
-
Authors
Illingworth, Peter J. http://orcid.org/0009-0008-1319-6643
Venetis, Christos
Gardner, David K.
Nelson, Scott M.
Berntsen, Jørgen
Larman, Mark G.
Agresta, Franca
Ahitan, Saran
Ahlström, Aisling http://orcid.org/0000-0002-5074-912X
Cattrall, Fleur
Cooke, Simon
Demmers, Kristy http://orcid.org/0009-0005-8610-1754
Gabrielsen, Anette
Hindkjær, Johnny
Kelley, Rebecca L.
Knight, Charlotte
Lee, Lisa http://orcid.org/0000-0002-0778-9636
Lahoud, Robert
Mangat, Manveen
Park, Hannah
Price, Anthony
Trew, Geoffrey
Troest, Bettina
Vincent, Anna
Wennerström, Susanne
Zujovic, Lyndsey
Hardarson, Thorir
-
Funding
Funding for this research was provided by:
Vitrolife, Sweden
- License Information
-
More Information
Article History
Received: 25 January 2024
Accepted: 29 June 2024
First Online: 9 August 2024
Competing interests
: P.J.I. has provided paid advice to Western Australia government on medical cases and has previously (until June 2022) held shares in Virtus Health, a commercial IVF company. C.V. has received consulting fees, lecture payments and travel expenses from pharmaceutical firms with a commercial portfolio in IVF, and has previously (until June 2022) held shares in Virtus Health, a commercial IVF company. D.K.G. has received a research grant from Vitrolife to develop culture medium. S.M.N. has received consulting fees, lecture payments and travel expenses from pharmaceutical firms with a commercial portfolio in IVF. J.B. and M.G.L. are employees of Vitrolife and own shares in Vitrolife, who have a pending iDAScore patent. R.L.K. has received a grant from a pharmaceutical firm with a commercial portfolio in IVF, has received speaking fees and travel expenses from Vitrolife, who have a pending iDAScore patent. R.L. has received lecture payments and travel expenses from pharmaceutical firms with a commercial portfolio in IVF. M.M. has received lecture payments and travel expenses from pharmaceutical firms with a commercial portfolio in IVF and has previously (until June 2022) held shares in Virtus Health, a commercial IVF company. H.P. and B.T. are employed by a company where Vitrolife funded research. T.H. was previously employed by Vitrolife, who have a pending iDAScore patent. The other authors declare no competing interests.
